lncRNA MSC-AS1 通过调控 miR-325/CCNG1 轴加重糖尿病肾病。
lncRNA MSC-AS1 Aggravates Diabetic Nephropathy by Regulating the miR-325/CCNG1 Axis.
机构信息
Department of Endocrinology, 960th Hospital Chinese Peoples Liberat Army, Tai'an, Shandong, China.
Department of Endocrine Rheumatology and Immunology, People's Hospital of Gaotang County, Liaocheng, Shandong, China.
出版信息
J Healthc Eng. 2022 Jan 25;2022:2279072. doi: 10.1155/2022/2279072. eCollection 2022.
BACKGROUND
Diabetic nephropathy (DN) is the most common microvascular complication of diabetes and has become the second leading cause of end-stage renal disease in the world. This study aims to clarify the regulatory mechanism of the lncRNA MSC-AS1/miR-325/cyclin G1 (CCNG1) axis in DN.
METHODS
The regulatory mechanism of lncRNA MSC-AS1/miR-325/CCNG1 was evaluated by RT-qPCR, CCK-8 assay, flow cytometry assay, RNA pull-down assay, ELISA, and western blot assay.
RESULTS
Upregulation of lncRNA MSC-AS1 was detected in DN patients and HRMC cells treated with high glucose (HG). Knockdown of lncRNA MSC-AS1 reduced the proliferation, fibrosis, and inflammation of HRMC cells induced by HG. In addition, lncRNA MSC-AS1 acts as a miR-325 sponge in the DN. CCNG1 is the direct target of miR-325, which can be positively regulated by lncRNA MSC-AS1 in DN. More importantly, downregulation of miR-325 and upregulation of CCNG1 can attenuate the protective effect of lncRNA MSC-AS1 knockdown on DN.
CONCLUSION
lncRNA MSC-AS1 aggravates DN by downregulating miR-325 and upregulating CCNG1.
背景
糖尿病肾病（DN）是糖尿病最常见的微血管并发症，已成为世界上第二大终末期肾病的病因。本研究旨在阐明 lncRNA MSC-AS1/miR-325/CCNG1 轴在 DN 中的调控机制。
方法
通过 RT-qPCR、CCK-8 测定、流式细胞术测定、RNA 下拉测定、ELISA 和 Western blot 测定评估 lncRNA MSC-AS1/miR-325/CCNG1 的调控机制。
结果
在 DN 患者和高糖（HG）处理的 HRMC 细胞中检测到 lncRNA MSC-AS1 的上调。lncRNA MSC-AS1 的敲低减少了 HG 诱导的 HRMC 细胞的增殖、纤维化和炎症。此外，lncRNA MSC-AS1 在 DN 中作为 miR-325 的海绵体起作用。CCNG1 是 miR-325 的直接靶标，可在 DN 中被 lncRNA MSC-AS1 正向调节。更重要的是，下调 miR-325 和上调 CCNG1 可以减弱 lncRNA MSC-AS1 敲低对 DN 的保护作用。
结论
lncRNA MSC-AS1 通过下调 miR-325 和上调 CCNG1 加重 DN。
Zotero 插件